Dario Roque, MD
Gynecologic Oncology · Chicago, ILNPI 1467682690
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Intuitive Surgical at 50.6% of the total. Among gynecologic oncology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 574 payments — averaging $1023.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$298K
- GSK$208K
- Merck$33K
- Tesaro, Inc.$27K
- Myriad Genetic Laboratories, Inc.$16K
- AbbVie$4K
- plus $2K from 12 others
Across 27 payments — averaging $21,997 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$477K
- Merck$68K
- Seagen Inc.$47K
- GSK$2K
What the payments were for
- Consulting fees$19,2603%
- Speaking & faculty fees$237,32640%
- Travel & lodging$52,0159%
- Food & beverage$21,4914%
- Education$257,39044%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 298 | $297,529 |
| GSK | 140 | $208,199 |
| Merck | 35 | $32,703 |
| Tesaro, Inc. | 43 | $26,740 |
| Myriad Genetic Laboratories, Inc. | 21 | $16,143 |
| AbbVie | 6 | $3,818 |
| AstraZeneca | 6 | $784 |
| Baxter Healthcare | 3 | $364 |
| Foundation Medicine, Inc. | 10 | $352 |
| Pacira Pharmaceuticals Incorporated | 1 | $221 |
| Medtronic | 1 | $168 |
| Immunogen, Inc. | 3 | $127 |
| Seagen Inc. | 1 | $98 |
| On Target Laboratories, Inc | 1 | $97 |
| Applied Medical Resources Corporation | 2 | $55 |
| Genentech USA, Inc. | 1 | $35 |
| Eisai Inc. | 1 | $30 |
| Roche Diagnostics Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$295,827
- JEMPERLI$156,197
- ZEJULA$76,651
- KEYTRUDA$16,815
- LYNPARZA$12,455
- PreciseTumor$5,775
- myChoice CDx$5,547
- myRisk$4,682
- Elahere$3,850
- EXPAREL$221
- LigaSure$168
- TISSEEL$148
- PerClot$110
- FLOSEAL$106
How this compares
$587,482 in reported general payments places this provider in the 95th percentile of 64 gynecologic oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 18 | $146 |
| Letrozole | 11 | $107 |
| Ondansetron Hcl | 17 | $65 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Chicago
- Amina AhmedChicago$1.1M
- Jenna MarcusChicago$230K
- Emily HinchcliffChicago$62K
- Summer DewdneyChicago$59K
- Kathryn MillsChicago$32K
- Wilberto Nieves-NeiraChicago$23K
- Amy AlexanderChicago$22K
- Freidoon AziziChicago$14K
- John MoroneyChicago$8K
- Emma BarberChicago$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.